JP2022542434A - 重水素化ｍｋ２経路阻害剤およびその使用方法 - Google Patents

重水素化ｍｋ２経路阻害剤およびその使用方法 Download PDF

Info

Publication number
JP2022542434A
JP2022542434A JP2022506384A JP2022506384A JP2022542434A JP 2022542434 A JP2022542434 A JP 2022542434A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022506384 A JP2022506384 A JP 2022506384A JP 2022542434 A JP2022542434 A JP 2022542434A
Authority
JP
Japan
Prior art keywords
disease
cancer
syndrome
autoimmune
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022506384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022542434A5 (OSRAM
Inventor
デイヴィッド ランドルフ アンダーソン
ゲイリー アンソニー デクレシェンツォ
Original Assignee
アクラリス セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクラリス セラピューティクス，インコーポレイテッド filed Critical アクラリス セラピューティクス，インコーポレイテッド
Publication of JP2022542434A publication Critical patent/JP2022542434A/ja
Publication of JP2022542434A5 publication Critical patent/JP2022542434A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022506384A 2019-07-31 2020-07-31 重水素化ｍｋ２経路阻害剤およびその使用方法 Ceased JP2022542434A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962881026P 2019-07-31 2019-07-31
US62/881,026 2019-07-31
PCT/US2020/044558 WO2021022186A1 (en) 2019-07-31 2020-07-31 Deuterated mk2 pathway inhibitors and methods of using the same

Publications (2)

Publication Number Publication Date
JP2022542434A true JP2022542434A (ja) 2022-10-03
JP2022542434A5 JP2022542434A5 (OSRAM) 2023-07-19

Family

ID=74228512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506384A Ceased JP2022542434A (ja) 2019-07-31 2020-07-31 重水素化ｍｋ２経路阻害剤およびその使用方法

Country Status (12)

Country Link
US (1) US12403141B2 (OSRAM)
EP (1) EP4003344A4 (OSRAM)
JP (1) JP2022542434A (OSRAM)
KR (1) KR20220041180A (OSRAM)
CN (1) CN114206339A (OSRAM)
AU (1) AU2020319879A1 (OSRAM)
BR (1) BR112022001324A2 (OSRAM)
CA (1) CA3149304A1 (OSRAM)
IL (1) IL290045A (OSRAM)
MX (1) MX2022001151A (OSRAM)
PH (1) PH12022550029A1 (OSRAM)
WO (1) WO2021022186A1 (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022019349A2 (pt) * 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
IL307187A (en) 2021-03-31 2023-11-01 Xinthera Inc MK2 inhibitors and their uses
KR20240035830A (ko) 2021-07-09 2024-03-18 신테라, 인크. 피리디논 mk2 저해제 및 이의 용도
WO2023001282A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 杂环取代的嘧啶衍生物
TWI836822B (zh) * 2021-12-29 2024-03-21 大陸商上海美悦生物科技發展有限公司 p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
CN116396274B (zh) * 2022-01-06 2025-11-11 深圳信立泰药业股份有限公司 一种取代的联吡啶酮类化合物及其制备方法与应用
CN116444493A (zh) * 2022-01-14 2023-07-18 上海翰森生物医药科技有限公司 含双并环类衍生物、其制备方法和应用
WO2023134764A1 (zh) 2022-01-14 2023-07-20 上海翰森生物医药科技有限公司 含吡啶多环类衍生物、其制备方法和应用
US20230286950A1 (en) * 2022-02-04 2023-09-14 Aclaris Therapeutics, Inc. Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds
WO2023165554A1 (zh) * 2022-03-03 2023-09-07 深圳信立泰药业股份有限公司 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用
WO2024149359A1 (zh) * 2023-01-13 2024-07-18 上海美悦生物科技发展有限公司 苯基取代的杂芳基类化合物及其药物组合物、制备方法和用途
US20260115177A1 (en) * 2023-01-13 2026-04-30 Poolbeg Pharma (UK) Limited Medicinal products and methods for the alleviation of cancer immunothera-py-associated cytokine release syndrome
WO2025093869A1 (en) * 2023-11-01 2025-05-08 Poolbeg Pharma (UK) Limited P38 map kinase inhibitor for use in the treatment of inflammation

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
US20110136861A1 (en) * 2009-07-28 2011-06-09 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase a2
JP2012528107A (ja) * 2009-05-28 2012-11-12 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
JP2013544889A (ja) * 2010-12-06 2013-12-19 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド 置換ピリジノンピリジニル化合物
JP2016520654A (ja) * 2013-06-07 2016-07-14 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
WO2017036432A1 (en) * 2015-09-02 2017-03-09 Zentiva, K.S. A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4— yl)urea and its deuterated analogs not containing dimeric impurities
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9359300B2 (en) * 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2017180589A1 (en) * 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
CN111727042A (zh) * 2017-12-06 2020-09-29 仁新医药私人有限公司 微管蛋白抑制剂
EP4114411A4 (en) 2020-03-02 2024-04-24 Washington University Compositions and methods for the treatment of pancreatic cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
JP2012528107A (ja) * 2009-05-28 2012-11-12 ノバルティス アーゲー ネプリライシン阻害剤としての置換アミノ酪酸誘導体
US20110136861A1 (en) * 2009-07-28 2011-06-09 Auspex Pharmaceuticals, Inc. Quinolone inhibitors of lipoprotein-associated phospholipase a2
JP2013544889A (ja) * 2010-12-06 2013-12-19 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド 置換ピリジノンピリジニル化合物
JP2016520654A (ja) * 2013-06-07 2016-07-14 コンフルエンス・ライフ・サイエンシズ，インコーポレーテッド メチル／フルオロ−ピリジニル−メトキシ置換ピリジノン−ピリジニル化合物及びフルオロ−ピリミジニル−メトキシ置換ピリジノン−ピリジニル化合物
WO2017036432A1 (en) * 2015-09-02 2017-03-09 Zentiva, K.S. A production method of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin- 4— yl)urea and its deuterated analogs not containing dimeric impurities
WO2018229683A1 (en) * 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases

Also Published As

Publication number Publication date
EP4003344A1 (en) 2022-06-01
US20220288070A1 (en) 2022-09-15
AU2020319879A1 (en) 2022-02-03
CN114206339A (zh) 2022-03-18
PH12022550029A1 (en) 2023-02-27
BR112022001324A2 (pt) 2022-03-22
KR20220041180A (ko) 2022-03-31
WO2021022186A1 (en) 2021-02-04
CA3149304A1 (en) 2021-02-04
IL290045A (en) 2022-03-01
US12403141B2 (en) 2025-09-02
MX2022001151A (es) 2022-02-22
EP4003344A4 (en) 2023-07-26

Similar Documents

Publication Publication Date Title
US12403141B2 (en) Deuterated MK2 pathway inhibitors and methods of using the same
US12297203B2 (en) Pyrrolopyrimidine ITK inhibitors
JP7607732B2 (ja) 置換ピロロピリミジンｊａｋ阻害剤ならびにこれを作製および使用する方法
US12616696B2 (en) Crystalline forms of (p)-3-chloro-4-((3,5-difluoropyridin-2-yl)methoxy)-2′-(2-(2-hydroxypropan-2-yl)pyrimidin-4-yl)-5′,6-dimethyl-2h-[1,4′-bipyridin]-2-one
US10800775B2 (en) Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
US20220235043A1 (en) Substituted sulfonamide pyrrolopyridines as jak inhibitors
US10316038B2 (en) Pyrrolopyrimidine ITK inhibitors for treating inflammation and cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230710

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230710

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241202

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250421